Verapamil hydrochloride tablet labels and packages

Verapamil
CALAN tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CALAN SR tablet extended release® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
VERAPAMIL HYDROCHLORIDE injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Verapamil
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

PRINCIPAL DISPLAY PANEL - 80 mg Label

NDC 0025-1851-31

100 Tablets Rx only

Calan® verapamil hydrochloride tablets

80 mg

Pfizer Distributed by G.D. Searle LLC Division of Pfizer Inc, NY, NY 10017

PRINCIPAL DISPLAY PANEL - 120 mg Label

NDC 0025-1861-31

100 Tablets Rx only

Calan® verapamil hydrochloride tablets

120 mg

Pfizer Distributed by G.D. Searle LLC Division of Pfizer Inc, NY, NY 10017